Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

Summary

The purpose of this study is to test whether Spironolactone can improve the severity of obstructive sleep apnea and improve cardiovascular biomarkers in people who are not regularly using their Positive Airway Pressure (PAP) therapy.

Timeline

Start

2022-03

Primary completion

2023-04

Completion

2023-04

Outcome

Outcome not reported

Stopped (Business): “Was on hold due to Covid then we were not able to initiate the funding again after such a long hold and loss of team members.”

Drugs

Indications